Fierce Pharma

DECEMBER 19, 2023

As the biopharma world readies for the turn of the calendar, the all-too-familiar topic of drug pricing once again presents an industry-wide overhang. Based on the series of measures centered on U.S. drug prices coming out of Washington, the Biden administration is clearly emboldened on the topic.

Biopharma 174

Biopharma Pharma 174

Fierce Pharma

JANUARY 3, 2024

Morgan Healthcare Conference rolled on in San Francisco, BioNTech, Alnylam and many other companies updated investors on their strategies heading into 2024. As the J.P. | As the J.P.

Biopharma 297

Biopharma Sales Healthcare Healthcare 297

MedCity News

FEBRUARY 14, 2024

2024 presents an exciting yet challenging landscape for global pharma marketers.

Marketing 96

Marketing Pharma Pharmaceutical Patients 96

Zymewire

APRIL 22, 2024

Summary of funding events, FDA approvals, clinical trial stats, and upcoming research and development plans from the world of biotech and pharma in Q1 2024

Biopharma 52

Biopharma FDA Pharma 52

pharmaphorum

APRIL 10, 2024

In another departure from its focus on genetic medicines, Vertex Pharma has agreed a $4.9 It is the largest acquisition in the biopharma sector so far in 2024. It is the largest acquisition in the biopharma sector so far in 2024.

Biopharma 95

Biopharma Medicine Pharma 95

Clarivate

APRIL 18, 2024

In 2024, watch as the global trendsetter brings to bear its technological expertise combined with a captive Prime membership, brand recognition, and national employer buy-in to re-envision healthcare that truly works around the patient. Healthcare segment) across the nation as part of a $1 billion cost-cutting strategy.

Retail 52

Retail Healthcare Healthcare Physicians 52

pharmaphorum

JANUARY 9, 2023

Biopharma and healthcare group Chiesi Farmaceutici S.p.A. is to acquire the 2015-established Amryt Pharma Plc. The post Chiesi expands rare disease portfolio with Amryt Pharma acquisition appeared first on. in an all-cash transaction at $14.50 per American Depositary Share (ADS). Each ADS represents five Amryt ordinary shares.

Pharma 91

Pharma Biopharma Management Medicine 91

Clarivate

OCTOBER 31, 2023

These years witnessed significant troughs in pharma financing, a drop in the capital markets, and an IPO window that remained firmly shut. Big pharma is still keen to access good technology, science, and assets, in many cases to plug a patent-expiry-shaped hole in their coffers. In short, the biotech bubble had burst. Pfizer’s $11.6

Pharma 52

Pharma Biopharma Marketing Healthcare 52

Clarivate

JANUARY 8, 2024

The annual Clarivate Drugs to Watch report for 2024 features 13 new therapeutics with standout commercial and/or clinical potential. The year 2024 is shaping up to be the best of times and the worst of times for the pharma industry,” said Henry Levy, President, Life Sciences & Healthcare at Clarivate.

Marketing 59

Marketing Patients Healthcare Healthcare 59

MedCity News

NOVEMBER 6, 2023

The biotech is preparing to advance its drug to Phase 3 testing in 2024. Celldex drug barzolvolimab has mid-stage results in a chronic inflammatory skin disease that top those of an approved Genentech drug and two experimental Novartis therapies.

Pharma 111

Pharma Biopharma 111

MedCity News

DECEMBER 20, 2023

GSK gains rights to a Hansoh Pharma antibody drug conjugate that targets a protein abundant on lung cancer cells and other types of solid tumors. The pharmaceutical giant plans to start its own slate of clinical trials with this ADC in 2024.

Pharma 102

Pharma Pharmaceutical Biopharma 102

MedCity News

OCTOBER 2, 2023

Novartis’s iptacopan met the first of two main goals in its pivotal study in immunoglobulin A nephropathy, and the pharma giant plans to seek accelerated FDA approval next year. The drug could challenge two available therapies for the rare kidney disorder.

FDA 99

FDA Pharma Biopharma 99

PM360

DECEMBER 20, 2023

With 2024 on the horizon, many in the biopharma space are taking stock of 2023 and what the current environment means for their potential success next year. This may best be achieved by large pharma companies, with their combined $200bn annual R&D budget, compared to smaller companies that are relying on external investment.

Biopharma 111

Biopharma Pharma Marketing Management 111

PM360

APRIL 22, 2024

The Unique Challenges of Patient/Pharma Interaction Patient engagement has become a critical component of medical marketing. With healthcare professionals becoming less accessible to biopharma reps, the emphasis has shifted toward patient empowerment. In biopharma, keeping the company safe becomes an added responsibility.

Patients 52

Patients Biopharma Ethics Marketing 52

PM360

MAY 10, 2024

May 9, 2024 /PRNewswire/ — VUE Health, a Boston-based healthcare advertising agency, has hired Zara Baker as Chief Digital Innovation Officer. Before that, she was the head of omnichannel strategy at Ionis Pharma and held senior digital roles at various healthcare and biopharma companies.

Healthcare 52

Healthcare Healthcare Biopharma Engineering 52

MedCity News

JANUARY 25, 2024

CG Oncology’s upsized IPO will support pivotal testing of cretostimogene, an oncolytic virus for non-muscle invasive bladder cancer. The clinical program spans tests of the engineered virus as a monotherapy and as part of combination treatments.

Engineering 114

Engineering Biopharma Pharma 114

MedCity News

DECEMBER 11, 2023

Novartis drug iptacopan, which won its first FDA approval in early December in a rare blood disorder, has met the main goal of a pivotal test in an ultra-rare kidney disease. The small molecule’s potential to address many diseases has stirred up blockbuster expectations.

FDA 100

FDA Biopharma Pharma 100

MedCity News

OCTOBER 30, 2023

Novartis drug candidate atrasentan met the main goal of a pivotal study in the chronic kidney disease IgA nepropathy. It’s one of two drugs added via the multi-billion dollar acquisition of Chinook Therapeutics; together with a homegrown therapeutic candidate, they give Novartis three different approaches to treat the rare disorder.

FDA 111

FDA Biopharma Pharma 111

MedCity News

NOVEMBER 9, 2023

AstraZeneca gains global rights to an oral GLP-1 agonist on track to reach Phase 2 testing in 2024. Under China-based Eccogene, the small molecule’s Phase 1 data show reductions in glucose and body weight.

Biopharma 112

Biopharma Pharma 112

MedCity News

DECEMBER 5, 2023

But Replimune’s therapy, an oncolytic virus, has better data in melanoma, and the company plans a 2024 FDA submission in this skin cancer. Replimune’s lead therapeutic candidate did not meet the two main goals of a study intended to support an FDA submission in cutaneous squamous cell carcinoma.

Leads 111

Leads FDA Biopharma Pharma 111

Clarivate

MAY 14, 2024

With only two3 GLP-1 drugs currently approved for weight loss—Huadong Medicine’s version of daily dosed liraglutide and thrice-a-day dosed beinaglutide from Benamae Pharma—the gap is substantial and leaves a solid market opportunity for weight loss drugs. What’s leading to the boom in development of semaglutide biosimilars?

Manufacturing 52

Manufacturing Marketing Leads Medicine 52

MedCity News

OCTOBER 5, 2023

The Orchard Therapeutics acquisition comes as the biotech’s gene therapy for metachromatic leukodystrophy approaches a March 2024 FDA decision. The ex vivo gene therapy is already commercialized in Europe, marketed as Libmeldy.

FDA 104

FDA Marketing Biopharma Pharma 104

MedCity News

OCTOBER 9, 2023

But Alnylam has other drugs candidates for the disease, including one expected to post Phase 3 data in the first half of 2024. Despite an affirmative FDA advisory committee vote, the agency declined to approve Alnylam Pharmaceuticals’ Onpattro for treating the heart complications caused by a rare, inherited protein disorder.

FDA 105

FDA Pharmaceutical Biopharma Pharma 105

MedCity News

OCTOBER 20, 2023

The most advanced of them is on track for an FDA submission in 2024. After paying $4 billion up front, Merck will share in the development and commercialization of three Daiichi Sankyo cancer drugs in the red-hot field of antibody drug conjugates, or ADCs.

FDA 98

FDA Biopharma Pharma 98

MedCity News

SEPTEMBER 26, 2023

Ionis plans early 2024 submissions for what could become the first medicine it commercializes without a partner. Ionis Pharmaceuticals’ olezarsen has Phase 3 results showing the therapy handily beat a placebo at reducing fat levels in the blood due to a rare, inherited metabolic disorder with no FDA-approved drugs.

Medicine 101

Medicine FDA Pharmaceutical Biopharma 101

MedCity News

APRIL 20, 2023

A lead program with preclinical proof-of-concept data in small cell lung cancer is on track to reach the clinic in 2024. Abdera Therapeutics emerged from stealth with technology that improves the way antibodies deliver radiopharmaceuticals for cancer.

Leads 100

Leads Biopharma Pharma 100

MedCity News

MAY 3, 2023

GSK plans to launch Arexvy in time for the 2023/2024 RSV season. FDA approval of GSK’s respiratory syncytial vaccine Arexvy covers adults age 60 and older—an age group at particular risk of developing severe complications from infection.

FDA 87

FDA Biopharma Pharma 87

MedCity News

JULY 10, 2023

A Phase 3 test of the nanoparticle-based therapy is expected to yield preliminary data in 2024. Johnson & Johnson is committing up to $60 million for global rights to a Nanobiotix therapy that enhances radiation treatment for head and neck cancer.

Leads 77

Leads Biopharma Pharma 77

MedCity News

MARCH 21, 2023

Sobi said it plans to seek FDA approval of the gout drug, SEL-212, in 2024. If approved, it would compete against Krystexxa, a Horizon Therapeutics drug projected to become a blockbuster seller.

FDA 74

FDA Biopharma Pharma 74

Pharmaceutical Technology

APRIL 4, 2023

The Boston, Massachusetts-based Scorpion expects to submit an investigational new drug (IND) application for STX-721 to the US Food and Drug Administration (FDA) in mid-2023, with an IND application for STX-241 expected in H1 2024. According to GlobalData’s Pharma Intelligence Centre, Tagrisso is forecasted to have global sales of $8.19

Food and Drug Administration 52

Food and Drug Administration Biopharma FDA Pharmaceutical 52

MedCity News

AUGUST 16, 2022

With the Series C financing, Senda aims to reach the clinic in 2024. Biotech startup Senda Biosciences is developing technology that yields a new type of medicine with two programming components: one directs the therapy to go to a particular destination in the body while the second tells the therapy what to do once it gets there.

Medicine 84

Medicine Biopharma Pharma 84

Clarivate

MAY 8, 2024

A glance at the 2023 and early 2024 life science dealmaking environment shows fewer, but higher-value, transactions. Other partnerships of note include one for a couple of Shanghai-based Elpiscience Biopharma Ltd’s preclinical bispecific antibody assets, licensed by Tokyo-based Astellas Pharma Inc, with the option to license two more.

Pharma 59

Pharma Biopharma Prospecting Competition 59

PM360

APRIL 22, 2024

With an ever- increasing demand for their time and attention, it is more difficult than ever for biopharma representatives to convey their message to the physician audience. In one survey, only 12% of HCPs said they felt biopharma companies are very effective at providing HCP education and training to them.

Education 59

Education Physicians Healthcare Healthcare 59

Clarivate

DECEMBER 14, 2023

Here are a few trends in life sciences and healthcare our analysts are keeping an eye on – and what they expect to see in 2024: Move over, oncology – metabolic drugs are the new hotness: The successful launches of Novo Nordisk’s Wegovy® and Eli Lilly’s Mounjaro® represent a revolutionary pharmacological breakthrough of rare proportions.

Pharma 111

Pharma Pharmacology Government Healthcare 111

European Pharmaceutical Review

NOVEMBER 30, 2023

For example, the GMP report stated that the contract development and manufacturing organisation (CDMO) eXmoor pharma, will be launching a cell and gene therapy process development and clinical manufacturing facility in Bristol. Licensing of the manufacturing suites is expected in early 2024.

Manufacturing 75

Manufacturing Recruitment Medicine Biopharma 75

European Pharmaceutical Review

APRIL 30, 2024

What are the top three trends that you are seeing in the biopharma manufacturing space? Let’s talk about continuous biopharma manufacturing. Speaking of your biopharma clients, what are you hearing about their main priorities? Sticking to the cell and gene therapy space, what’s your main prediction for 2024?

Manufacturing 78

Manufacturing Food and Drug Administration Biopharma Marketing 78

Clarivate

MAY 13, 2024

According to Clarivate’s latest enrollment data, as of January 2024, Medicaid enrollment had plummeted by nearly 9 million compared to six months prior. For 2024, 18% of enrollees were new to exchange coverage, according to the Centers for Medicare and Medicaid Services. million between January 2023 and January 2024. to about 2.5

Insurance 52

Insurance Marketing Healthcare Healthcare 52